Flamingo doses first subject in Phase II head and neck carcinoma trial

https://www.clinicaltrialsarena.com/news/flamingo-head-neck-carcinoma-trial/?cf-view

Flamingo Therapeutics has initiated the Phase II PEMDA-HN clinical trial by dosing the first subject. The trial focuses on evaluating the combination of danvatirsen and Merck’s Keytruda for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Danvatirsen, Flamingo's lead oncology program, targets signal transducer and activator of transcription 3 (STAT3) and has shown clinical activity in HNSCC. The international trial, conducted in multiple centres across the UK, the US, and Korea, compares the safety and efficacy of the danvatirsen and pembrolizumab combination against pembrolizumab monotherapy as a first-line treatment for patients with programmed death-ligand 1 (PD-L1) expressing tumours. The study aims to improve overall response rates for HNSCC patients by leveraging the potential synergy of the mechanisms of action between the two therapies. Flamingo is dedicated to developing RNA-targeted therapies for oncology, focusing on traditionally challenging targets like transcription factors and long non-coding RNAs.